Vector and Children’s Hospital Boston’s Technology and Innovation Development Office (TIDO) at will be enthusiastic participants in next week’s BioPharm America conference (Sept 7-9). In between networking with industry colleagues and pitching technologies developed at Children’s, we’ll be providing blog coverage and live-tweeting from the sessions under the hashtag #BPA11.
Since BioPharm is in Boston this year, we’re also heavily involved as presenters. Bruce Zetter of Children’s Vascular Biology program will speak about cancer biomarkers on a Wednesday panel titled Lessons Learned in Personalized Medicine in Oncology. Leonard Zon, director of Children’s Stem Cell Program, will describe the development of stem-cell-boosting drugs as part of a Friday panel titled Stem Cells and Drug Discovery: Confronting the Translational Imperative.
Halvorsen elaborates on this theme in an interview for the online life sciences journal Partnering News. About four years ago, he morphed Children’s Intellectual Property Office into TIDO, broadening his team’s focus from solely patenting and licensing to actively fostering and advancing innovation within the hospital, awarding grants to further the most promising projects and outsourcing preclinical work as compound analoguing, pharmacokinetic assays and device prototyping.
As Halvorsen puts it in Partnering News (Read the full article here):
“It is critically important that industry/academic partnerships continue to form and evolve. Big pharma must maintain its research and development activities, and its capacity to innovate. Academic medical centers need committed partners with product development capabilities through regulatory approval and distribution.
“Industry and academia must get away from the old way of doing things, take risks and support new possibilities for collaboration—our patients deserve it.”